


DarioHealth | Company Overview

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease treatment, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down.

Quarterly Revenue



Key Stats at a Glance



Strong Revenue Growth

~\$5M
2017 revenue (projected)



Multiple Growth Drivers

493m
People with diabetes projected by 2045

471m
Pre-diabetes projected by 2035*



Global Market Penetration

5
Countries fully reimbursed

4
Regulatory bodies approvals/clearance



Growing Market Opportunity

425m
People with diabetes (2017)



Scalable Diabetes Management Platform

7
Countries with users



Experienced Management Team

2011
Founded
New York and Israel
Global presence

40
Employees

* Pre-diabetes diagnosis and treatment: A review, by Nihdi Elansal, 15 Mar 2015

DarioHealth has grown to a mature organization that is fully data-driven and capable of providing robust, managed care solutions.



Select Financials & Facts

Nasdaq Ticker:	DRIO
Closing Price at 11/10/17:	\$1.58
52-Week Range:	\$1.40 - \$4.70
Shares (11/10/17) O/S:	10.4M
Est. Public Float:	6.8M
Market Cap (11/10/17):	\$16.2M
FY16 Revenue:	\$2.8M
Cash (9/30/17):	\$6.3M
Fiscal Year-end:	12/31

Providing Value Across the Health Continuum



User-centric,
Data-driven
Personalized Health



Helps Improve
Clinical
Outcomes



Minimal Healthcare
Costs

Balance Sheet Highlights

\$ in thousands	9/30/17 (unaudited)	12/31/16
Cash & cash equivalents	\$6,262	\$1,093
Total assets	\$9,457	\$3,872
Liability related to warrants	\$2	\$7,488
Total liabilities	\$3,342	\$10,413
Shareholders' equity (deficiency)	\$6,115	(\$6,541)



Erez Raphael, Chairman & CEO
DarioHealth Corp.
142 W 57th Street, 8th Floor
New York, NY 10019
USA

partnershipgroup@dariohealth.com
www.dariohealth.com



**WESTWICKE
PARTNERS**

Investor Relations
Westwicke Partners
Tel: 1-443-213-0500
Dario@Westwicke.com
www.westwickepartners.com